<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812331</url>
  </required_header>
  <id_info>
    <org_study_id>CR012604</org_study_id>
    <secondary_id>TMC435350-TiDP16-C202</secondary_id>
    <nct_id>NCT00812331</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)</brief_title>
  <official_title>An Open-label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec Pharmaceuticals, Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec Pharmaceuticals, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess anti-viral activity (inhibition of viral growth) of
      TMC435350 in genotype 2,3,4,5 and 6 hepatitis C virus infected participants who have never
      received treatment for their hepatitis C infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know the identity of the intervention) study to assess the
      antiviral activity, safety, tolerability and pharmacokinetics (explores what the body does to
      the medication) of TMC435350 hereafter referred to as TMC435. Approximately 40 participants
      will be divided in 5 groups as per the genotype (8 participants each group). The study will
      include a screening phase (up to 6 weeks), treatment phase (7 days) and a follow-up phase
      (30-35 days after the last dose of study medication). Safety evaluations will include
      assessment of adverse events, clinical laboratory tests and cardiovascular safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels</measure>
    <time_frame>Baseline, Day 3, and Day 7</time_frame>
    <description>The table below shows the mean changes from baseline in HCV RNA values (log10 IU/mL) per genotype on Day 3 and Day 7 during the TMC435 treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease From Baseline of Greater Than or Equal to 2 log10 IU/mL in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During the TMC435 Treatment Period</measure>
    <time_frame>Baseline, Day 3, Day 5 and Day 7</time_frame>
    <description>The table below shows the number of participants with a decrease from baseline of greater than or equal to 2 log10 IU/mL in HCV RNA during the 7-day TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Below the Limit of Quantification (Less Than 25 IU/mL) and Limit of Detection (Less Than 25 IU/mL Undetectable) During the TMC435 Treatment Period</measure>
    <time_frame>Baseline, Day 3, Day 5 and Day 7</time_frame>
    <description>The table below shows the number of participants with plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels below limit of quantification (less than 25 IU/mL) and limit of detection (less than 25 IU/mL undetectable), respectively, during the 7-day TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Viral Breakthrough During TMC435 Treatment Period</measure>
    <time_frame>During the 7-day of TMC435 treatment period</time_frame>
    <description>The table below shows the number of participants who experienced viral breakthrough (defined as an increase greater than 1 log10 IU/mL in plasma level of hepatitis C virus [HCV] ribonucleic acid [RNA] from the lowest level reached, or a HCV RNA level greater than 100 IU/mL in participants who previously had HCV RNA levels undetectable [less than 25 IU/mL undetectable] or not quantifiable [less than 25 IU/mL detectable]) during the 7-day TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Plasma Concentration (C0h) of TMC435</measure>
    <time_frame>Predose on Day 7</time_frame>
    <description>The table below shows the median predose plasma concentration (C0h) for all participants on Day 7 of the TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the median minimum plasma concentration (Cmin) for all participants on Day 7 of the TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the median maximum plasma concentration (Cmax) for all participants by genotype of hepatitis C virus infection on Day 7 of the TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the median time in hours for all participants (by genotype of hepatitis C virus infection) to reach the maximum plasma concentration (tmax) of TMC435 following treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Steady-State Plasma Concentration (Css,av) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the average steady-state TMC435 plasma concentration (Css,av) for all participants by genotype of hepatitis C virus infection on Day 7 during the TMC435 treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation Index (FI) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the percentage of fluctuation (FI) (defined as the variation between maximum and minimum TMC435 plasma concentrations at steady-state) of TMC435 on Day 7 for participants by genotype of hepatitis C virus infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24h) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the area under the plasma concentration-time curve from the time of administration up to 24 hours after dosing (AUC24h) of TMC435 on Day 7 for all participants by genotype of hepatitis C virus infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time of Administration up to the Last Time Point With a Measurable Concentration After Dosing (AUClast) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the area under the plasma concentration-time curve from time of administration up to the last time point with a measurable concentration after dosing (AUClast) on Day 7 for TMC435 by genotype of hepatitis C virus infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>In the table below, median values for the elimination rate constant (the rate at which a drug is removed from the body expressed per unit of time, e.g., fraction/hour) for TMC435 are shown for participants by genotype of hepatitis C virus infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2,Term) of TMC435</measure>
    <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
    <description>The table below shows the terminal plasma half-life for TMC435 in participants analyzed by genotype of hepatitis C virus infection. The terminal plasma half-life of a drug is the time in hours required for the concentration of a drug in the body to fall to 50% after having reached a state of equilibrium following administration.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 2 hepatitis C virus (HCV) infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 3 HCV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 4 HCV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 5 HCV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 6 HCV infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC435</intervention_name>
    <description>From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.</description>
    <arm_group_label>Genotype 2</arm_group_label>
    <arm_group_label>Genotype 3</arm_group_label>
    <arm_group_label>Genotype 4</arm_group_label>
    <arm_group_label>Genotype 5</arm_group_label>
    <arm_group_label>Genotype 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with documented chronic genotype 2, 3, 4, 5 or 6 hepatitis C virus (HCV)
             infection

          -  Participants who have never received treatment for their HCV infection

          -  Participants with either no cirrhosis or up to Child Pugh A liver disease

          -  Participants with plasma HCV genotype level of more than or equal to 100, 000 IU/mL at
             screening

        Exclusion Criteria:

          -  Evidence of Child Pugh B or C liver disease at screening, decompensated liver disease
             defined as prior or current history of ascities, hepatic encephalopathy, esophageal or
             gastric varices

          -  Participants with diagnosed or suspected hepatocellular carcinoma

          -  Participants coinfected with human immunodeficiency virus type 1 or 2, or hepatitis A
             or B virus infection or active tuberculosis at screening

          -  Participants with any active clinically significant disease, or medical history or
             physical examination or electrocardiogram findings during screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec Pharmaceuticals, Ireland Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec Pharmaceuticals, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt N/A</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>December 24, 2013</results_first_submitted>
  <results_first_submitted_qc>July 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2014</results_first_posted>
  <disposition_first_submitted>March 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2013</disposition_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>TMC435</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 37 participants from 3 countries were enrolled and started treatment in the study (17 participants in Belgium, 12 participants in Germany, and 8 participants in Thailand).</recruitment_details>
      <pre_assignment_details>A total of 48 participants were screened of which 11 participants were not treated with TMC435. A total of 37 participants received study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Genotype 2</title>
          <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Genotype 3</title>
          <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Genotype 4</title>
          <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="P4">
          <title>Genotype 5</title>
          <description>Participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="P5">
          <title>Genotype 6</title>
          <description>Participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotype 2</title>
          <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Genotype 3</title>
          <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Genotype 4</title>
          <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Genotype 5</title>
          <description>Participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="B5">
          <title>Genotype 6</title>
          <description>Participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="27" upper_limit="61"/>
                    <measurement group_id="B2" value="42" lower_limit="18" upper_limit="56"/>
                    <measurement group_id="B3" value="47" lower_limit="26" upper_limit="55"/>
                    <measurement group_id="B4" value="65" lower_limit="48" upper_limit="69"/>
                    <measurement group_id="B5" value="49" lower_limit="30" upper_limit="53"/>
                    <measurement group_id="B6" value="48" lower_limit="18" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels</title>
        <description>The table below shows the mean changes from baseline in HCV RNA values (log10 IU/mL) per genotype on Day 3 and Day 7 during the TMC435 treatment period.</description>
        <time_frame>Baseline, Day 3, and Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels</title>
          <description>The table below shows the mean changes from baseline in HCV RNA values (log10 IU/mL) per genotype on Day 3 and Day 7 during the TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="0.625" lower_limit="-3.6" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="0.16" spread="0.263" lower_limit="-0.7" upper_limit="1.8"/>
                    <measurement group_id="O3" value="-3.43" spread="0.167" lower_limit="-3.9" upper_limit="-2.6"/>
                    <measurement group_id="O4" value="-2.71" spread="0.335" lower_limit="-4.0" upper_limit="-1.5"/>
                    <measurement group_id="O5" value="-3.57" spread="0.197" lower_limit="-4.2" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="0.538" lower_limit="-4.2" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="-0.13" spread="0.175" lower_limit="-1.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="-3.66" spread="0.320" lower_limit="-4.7" upper_limit="-2.3"/>
                    <measurement group_id="O4" value="-2.43" spread="0.357" lower_limit="-3.2" upper_limit="-0.7"/>
                    <measurement group_id="O5" value="-4.40" spread="0.222" lower_limit="-5.2" upper_limit="-3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease From Baseline of Greater Than or Equal to 2 log10 IU/mL in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During the TMC435 Treatment Period</title>
        <description>The table below shows the number of participants with a decrease from baseline of greater than or equal to 2 log10 IU/mL in HCV RNA during the 7-day TMC435 treatment period.</description>
        <time_frame>Baseline, Day 3, Day 5 and Day 7</time_frame>
        <population>Intent-to-treat (ITT) Population- all randomized subjects who received at least 1 dose of study medication (TMC435)</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease From Baseline of Greater Than or Equal to 2 log10 IU/mL in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During the TMC435 Treatment Period</title>
          <description>The table below shows the number of participants with a decrease from baseline of greater than or equal to 2 log10 IU/mL in HCV RNA during the 7-day TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) Population- all randomized subjects who received at least 1 dose of study medication (TMC435)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Below the Limit of Quantification (Less Than 25 IU/mL) and Limit of Detection (Less Than 25 IU/mL Undetectable) During the TMC435 Treatment Period</title>
        <description>The table below shows the number of participants with plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels below limit of quantification (less than 25 IU/mL) and limit of detection (less than 25 IU/mL undetectable), respectively, during the 7-day TMC435 treatment period.</description>
        <time_frame>Baseline, Day 3, Day 5 and Day 7</time_frame>
        <population>Intent-to-treat (ITT) Population - all randomized subjects who received at least 1 dose of study medication (TMC435)</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Below the Limit of Quantification (Less Than 25 IU/mL) and Limit of Detection (Less Than 25 IU/mL Undetectable) During the TMC435 Treatment Period</title>
          <description>The table below shows the number of participants with plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels below limit of quantification (less than 25 IU/mL) and limit of detection (less than 25 IU/mL undetectable), respectively, during the 7-day TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) Population - all randomized subjects who received at least 1 dose of study medication (TMC435)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3 (less than 25 IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (less than 25 IU/mL undetectable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (less than 25 IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (less than 25 IU/mL undetectable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (less than 25 IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (less than 25 IU/mL undetectable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Viral Breakthrough During TMC435 Treatment Period</title>
        <description>The table below shows the number of participants who experienced viral breakthrough (defined as an increase greater than 1 log10 IU/mL in plasma level of hepatitis C virus [HCV] ribonucleic acid [RNA] from the lowest level reached, or a HCV RNA level greater than 100 IU/mL in participants who previously had HCV RNA levels undetectable [less than 25 IU/mL undetectable] or not quantifiable [less than 25 IU/mL detectable]) during the 7-day TMC435 treatment period.</description>
        <time_frame>During the 7-day of TMC435 treatment period</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Viral Breakthrough During TMC435 Treatment Period</title>
          <description>The table below shows the number of participants who experienced viral breakthrough (defined as an increase greater than 1 log10 IU/mL in plasma level of hepatitis C virus [HCV] ribonucleic acid [RNA] from the lowest level reached, or a HCV RNA level greater than 100 IU/mL in participants who previously had HCV RNA levels undetectable [less than 25 IU/mL undetectable] or not quantifiable [less than 25 IU/mL detectable]) during the 7-day TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predose Plasma Concentration (C0h) of TMC435</title>
        <description>The table below shows the median predose plasma concentration (C0h) for all participants on Day 7 of the TMC435 treatment period.</description>
        <time_frame>Predose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Predose Plasma Concentration (C0h) of TMC435</title>
          <description>The table below shows the median predose plasma concentration (C0h) for all participants on Day 7 of the TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3720" lower_limit="164" upper_limit="8420"/>
                    <measurement group_id="O2" value="1310" lower_limit="492" upper_limit="4220"/>
                    <measurement group_id="O3" value="6270" lower_limit="1030" upper_limit="13100"/>
                    <measurement group_id="O4" value="4650" lower_limit="80.1" upper_limit="14500"/>
                    <measurement group_id="O5" value="5440" lower_limit="2280" upper_limit="11700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Plasma Concentration (Cmin) of TMC435</title>
        <description>The table below shows the median minimum plasma concentration (Cmin) for all participants on Day 7 of the TMC435 treatment period.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Plasma Concentration (Cmin) of TMC435</title>
          <description>The table below shows the median minimum plasma concentration (Cmin) for all participants on Day 7 of the TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3320" lower_limit="156" upper_limit="8420"/>
                    <measurement group_id="O2" value="1110" lower_limit="463" upper_limit="3440"/>
                    <measurement group_id="O3" value="5450" lower_limit="1030" upper_limit="13100"/>
                    <measurement group_id="O4" value="4230" lower_limit="48.2" upper_limit="14300"/>
                    <measurement group_id="O5" value="4960" lower_limit="2080" upper_limit="10600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of TMC435</title>
        <description>The table below shows the median maximum plasma concentration (Cmax) for all participants by genotype of hepatitis C virus infection on Day 7 of the TMC435 treatment period.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of TMC435</title>
          <description>The table below shows the median maximum plasma concentration (Cmax) for all participants by genotype of hepatitis C virus infection on Day 7 of the TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11250" lower_limit="2360" upper_limit="18500"/>
                    <measurement group_id="O2" value="6580" lower_limit="2760" upper_limit="13200"/>
                    <measurement group_id="O3" value="13500" lower_limit="4530" upper_limit="26200"/>
                    <measurement group_id="O4" value="13600" lower_limit="215" upper_limit="24700"/>
                    <measurement group_id="O5" value="14800" lower_limit="3460" upper_limit="23000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</title>
        <description>The table below shows the median time in hours for all participants (by genotype of hepatitis C virus infection) to reach the maximum plasma concentration (tmax) of TMC435 following treatment.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</title>
          <description>The table below shows the median time in hours for all participants (by genotype of hepatitis C virus infection) to reach the maximum plasma concentration (tmax) of TMC435 following treatment.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" lower_limit="4.00" upper_limit="7.83"/>
                    <measurement group_id="O2" value="6.025" lower_limit="4.02" upper_limit="10.08"/>
                    <measurement group_id="O3" value="6.04" lower_limit="4.00" upper_limit="8.08"/>
                    <measurement group_id="O4" value="6.00" lower_limit="4.00" upper_limit="8.02"/>
                    <measurement group_id="O5" value="6.00" lower_limit="4.00" upper_limit="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Steady-State Plasma Concentration (Css,av) of TMC435</title>
        <description>The table below shows the average steady-state TMC435 plasma concentration (Css,av) for all participants by genotype of hepatitis C virus infection on Day 7 during the TMC435 treatment period.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Steady-State Plasma Concentration (Css,av) of TMC435</title>
          <description>The table below shows the average steady-state TMC435 plasma concentration (Css,av) for all participants by genotype of hepatitis C virus infection on Day 7 during the TMC435 treatment period.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7115" lower_limit="1110" upper_limit="12870"/>
                    <measurement group_id="O2" value="3081" lower_limit="1410" upper_limit="7550"/>
                    <measurement group_id="O3" value="8843" lower_limit="2954" upper_limit="20340"/>
                    <measurement group_id="O4" value="7850" lower_limit="130.8" upper_limit="19660"/>
                    <measurement group_id="O5" value="9354" lower_limit="2602" upper_limit="16180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluctuation Index (FI) of TMC435</title>
        <description>The table below shows the percentage of fluctuation (FI) (defined as the variation between maximum and minimum TMC435 plasma concentrations at steady-state) of TMC435 on Day 7 for participants by genotype of hepatitis C virus infection.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluctuation Index (FI) of TMC435</title>
          <description>The table below shows the percentage of fluctuation (FI) (defined as the variation between maximum and minimum TMC435 plasma concentrations at steady-state) of TMC435 on Day 7 for participants by genotype of hepatitis C virus infection.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>% fluctuation</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.2" lower_limit="78.35" upper_limit="210.4"/>
                    <measurement group_id="O2" value="149.4" lower_limit="100.3" upper_limit="246.3"/>
                    <measurement group_id="O3" value="95.38" lower_limit="56.77" upper_limit="161.1"/>
                    <measurement group_id="O4" value="93.12" lower_limit="52.91" upper_limit="129.3"/>
                    <measurement group_id="O5" value="88.16" lower_limit="53.04" upper_limit="127.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24h) of TMC435</title>
        <description>The table below shows the area under the plasma concentration-time curve from the time of administration up to 24 hours after dosing (AUC24h) of TMC435 on Day 7 for all participants by genotype of hepatitis C virus infection.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - as all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24h) of TMC435</title>
          <description>The table below shows the area under the plasma concentration-time curve from the time of administration up to 24 hours after dosing (AUC24h) of TMC435 on Day 7 for all participants by genotype of hepatitis C virus infection.</description>
          <population>Intent-to-treat (ITT) population - as all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>ng*h/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170100" lower_limit="26350" upper_limit="311000"/>
                    <measurement group_id="O2" value="74670" lower_limit="34500" upper_limit="199500"/>
                    <measurement group_id="O3" value="212000" lower_limit="70400" upper_limit="483000"/>
                    <measurement group_id="O4" value="189000" lower_limit="3084" upper_limit="457600"/>
                    <measurement group_id="O5" value="227100" lower_limit="63430" upper_limit="373500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time of Administration up to the Last Time Point With a Measurable Concentration After Dosing (AUClast) of TMC435</title>
        <description>The table below shows the area under the plasma concentration-time curve from time of administration up to the last time point with a measurable concentration after dosing (AUClast) on Day 7 for TMC435 by genotype of hepatitis C virus infection.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time of Administration up to the Last Time Point With a Measurable Concentration After Dosing (AUClast) of TMC435</title>
          <description>The table below shows the area under the plasma concentration-time curve from time of administration up to the last time point with a measurable concentration after dosing (AUClast) on Day 7 for TMC435 by genotype of hepatitis C virus infection.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>ng*h/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268000" lower_limit="31400" upper_limit="712600"/>
                    <measurement group_id="O2" value="111500" lower_limit="43680" upper_limit="272000"/>
                    <measurement group_id="O3" value="365500" lower_limit="99320" upper_limit="1179000"/>
                    <measurement group_id="O4" value="360000" lower_limit="3770" upper_limit="944400"/>
                    <measurement group_id="O5" value="411100" lower_limit="117500" upper_limit="798900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant of TMC435</title>
        <description>In the table below, median values for the elimination rate constant (the rate at which a drug is removed from the body expressed per unit of time, e.g., fraction/hour) for TMC435 are shown for participants by genotype of hepatitis C virus infection.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant of TMC435</title>
          <description>In the table below, median values for the elimination rate constant (the rate at which a drug is removed from the body expressed per unit of time, e.g., fraction/hour) for TMC435 are shown for participants by genotype of hepatitis C virus infection.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>1/hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05042" lower_limit="0.01776" upper_limit="0.08666"/>
                    <measurement group_id="O2" value="0.06024" lower_limit="0.04057" upper_limit="0.08552"/>
                    <measurement group_id="O3" value="0.04308" lower_limit="0.01803" upper_limit="0.06955"/>
                    <measurement group_id="O4" value="0.03826" lower_limit="0.03315" upper_limit="0.07737"/>
                    <measurement group_id="O5" value="0.03784" lower_limit="0.01826" upper_limit="0.05926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2,Term) of TMC435</title>
        <description>The table below shows the terminal plasma half-life for TMC435 in participants analyzed by genotype of hepatitis C virus infection. The terminal plasma half-life of a drug is the time in hours required for the concentration of a drug in the body to fall to 50% after having reached a state of equilibrium following administration.</description>
        <time_frame>Predose, and at 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose on Day 7</time_frame>
        <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype 2</title>
            <description>Participants with chronic genotype 2 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Genotype 3</title>
            <description>Participants with chronic genotype 3 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Genotype 4</title>
            <description>Participants with chronic genotype 4 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Genotype 5</title>
            <description>participants with chronic genotype 5 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Genotype 6</title>
            <description>participants with chronic genotype 6 HCV infection who received 200 mg TMC435 as a single oral ((by mouth) dose once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2,Term) of TMC435</title>
          <description>The table below shows the terminal plasma half-life for TMC435 in participants analyzed by genotype of hepatitis C virus infection. The terminal plasma half-life of a drug is the time in hours required for the concentration of a drug in the body to fall to 50% after having reached a state of equilibrium following administration.</description>
          <population>Intent-to-treat (ITT) population - all randomized participants who received at least 1 dose of study medication (TMC435).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" lower_limit="7.998" upper_limit="39.04"/>
                    <measurement group_id="O2" value="11.51" lower_limit="8.105" upper_limit="17.09"/>
                    <measurement group_id="O3" value="16.09" lower_limit="9.966" upper_limit="38.44"/>
                    <measurement group_id="O4" value="18.12" lower_limit="8.959" upper_limit="20.91"/>
                    <measurement group_id="O5" value="18.32" lower_limit="11.70" upper_limit="37.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of signing of the Informed Consent Form onwards until 30-35 days after last TMC435 intake.</time_frame>
      <desc>5% cutoff is restricted to Total group. Adverse events reported for the total group rather than by genotype because enrollment numbers by genotype were small.</desc>
      <group_list>
        <group group_id="E1">
          <title>Total</title>
          <description>Participants with chronic genotype 2,3,4,5 or 6 HCV infection who received 200 mg TMC435 as a single oral (by mouth) dose once daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical DVLP Manager</name_or_title>
      <organization>Janssen Research &amp; Development United States</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

